ライフサイエンスコーパス: tularemia

1 vaccines and therapeutics against pneumonic tularemia.

2 for virulence in a mouse pulmonary model of tularemia.

3 embryos and in the murine model of pneumonic tularemia.

4 and is the etiological agent of the disease tularemia.

5 ns in intranasal inoculation mouse models of tularemia.

6 ncisella tularensis causes the human disease tularemia.

7 the role of type I IFNs in a mouse model of tularemia.

8 e highly infectious animal and human disease tularemia.

9 ancisella tularensis, the causative agent of tularemia.

10 sed clinically to improve treatments against tularemia.

11 uses a lethal infection that resembles human tularemia.

12 e attributes in a mouse model of respiratory tularemia.

13 macrophages and a mouse model of respiratory tularemia.

14 ellular bacterium, is the etiologic agent of tularemia.

15 is a highly infectious pathogen that causes tularemia.

16 cellular pathogen and the causative agent of tularemia.

17 r smallpox and botulism than for anthrax and tularemia.

18 cellular pathogen and the causative agent of tularemia.

19 ellular bacterium, is the causative agent of tularemia.

20 sis infects wild animals and humans to cause tularemia.

21 t causes a potentially lethal disease called tularemia.

22 ium that is the causative agent of pulmonary tularemia.

23 lls following inhalation in a mouse model of tularemia.

24 ses the potentially life-threatening disease tularemia.

25 the causative agent of the zoonotic disease tularemia.

26 cellular pathogen and the etiologic agent of tularemia.

27 racellular pathogen that causes the zoonosis tularemia.

28 resistance to F. novicida-induced pneumonic tularemia.

29 leading to protective immunity to pneumonic tularemia.

30 ver and spleen in a mouse model of pulmonary tularemia.

31 ys a role in the pathogenesis of respiratory tularemia.

32 at the IL-23 response may be relevant during tularemia.

33 tants may be useful for immunization against tularemia.

34 ive coccobacillus, is the causative agent of tularemia.

35 ancisella tularensis, the causative agent of tularemia.

36 fectious pathogen and the causative agent of tularemia.

37 ellular bacterium, is the etiologic agent of tularemia.

38 be of use in the design of a vaccine against tularemia.

39 sella tularensis causes the zoonotic disease tularemia.

40 in tempering the host response to pneumonic tularemia.

41 lar pathogen and is the etiological agent of tularemia.

42 m that causes an acute, fatal disease called tularemia.

43 cisella tularensis is the causative agent of tularemia.

44 ative coccobacillus that causes the zoonosis tularemia.

45 tive immunity in protection from respiratory tularemia.

46 agents potentially efficacious for treating tularemia.

47 of cell types and is the causative agent of tularemia.

48 Mice were infected to produce respiratory tularemia.

49 ring requires special media and suspicion of tularemia.

50 the causative agent of the zoonotic disease tularemia.

51 identify risk factors for primary pneumonic tularemia.

52 None of them developed signs or symptoms of tularemia.

53 the laboratory of the clinical suspicion of tularemia.

54 2000, and had a positive laboratory test for tularemia.

55 ia; 11 of these cases were primary pneumonic tularemia.

56 cisella tularensis is the causative agent of tularemia.

57 ship to Francisella tularensis, the agent of tularemia.

58 egative bacterium, is the causative agent of tularemia.

59 s contracted laboratory-verified respiratory tularemia.

60 m that causes the potentially lethal disease tularemia.

61 negative pathogen and the causative agent of tularemia.

62 therapeutic benefits for protection against tularemia.

63 cellular pathogen and the causative agent of tularemia.

64 erium and the causative agent of the disease tularemia.

65 acterial pathogen and the causative agent of tularemia.

66 bacterium that causes the zoonotic infection tularemia.

67 ve agent of the debilitating febrile illness tularemia.

68 rtant human pathogen responsible for causing tularemia.

69 ese cells in the protective host response to tularemia.

70 ophages and are avirulent in mouse models of tularemia.

71 ghly virulent in humans, causing the disease tularemia.

72 ar pathogen that causes the zoonotic disease tularemia.

73 n of this organism as a vaccine platform for tularemia.

74 cisella tularensis is the causative agent of tularemia.

75 and is the etiological agent of the disease tularemia.

76 ctive during infection in the mouse model of tularemia.

77 ensis causes a lethal human disease known as tularemia.

78 ntibody Ab52 in a mouse model of respiratory tularemia.

79 ent bacteria that cause the zoonotic disease tularemia.

80 e damage that characterizes lethal pneumonic tularemia.

81 the wild type in a mouse model of pneumonic tularemia.

82 virulent in the murine model of subcutaneous tularemia.

83 ely reduced in the murine model of pneumonic tularemia.

84 We identified 15 patients with tularemia; 11 of these cases were primary pneumonic tula

85 Mass., has been the site of two outbreaks of tularemia (1978 and 2000).

86 s of 121 of 190 patients (64%) reported with tularemia; 79 (65%) were males; the median age was 37 ye

87 y grow within mammalian hosts, often causing tularemia, a fatal disease.

88 Francisella tularensis causes tularemia, a highly contagious disease of animals and hu

89 ularensis is the causative agent of zoonotic tularemia, a severe pneumonia in humans, and Francisella

90 n ophthalmological manifestations related to tularemia, a zoonose caused by the bacterium Francisella

91 cisella tularensis is the causative agent of tularemia, a zoonosis that can affect humans with potent

92 erial pathogen Francisella tularensis causes tularemia, a zoonosis that can be fatal.

93 s currently available for protection against tularemia, although an attenuated strain, dubbed the liv

94 cisella tularensis is the causative agent of tularemia and a category A potential agent of bioterrori

95 ive bacterium that is the causative agent of tularemia and a potential bioweapon.

96 e nearest neighbor to the causative agent of tularemia and category A select agent Francisella tulare

97 l features may prompt clinicians to consider tularemia and facilitate appropriate testing.

98 and consideration as potential vaccines for tularemia and for identification of immunological correl

99 subsp. tularensis is the etiologic agent of tularemia and has been designated a category A biothreat

100 egative bacterium, is the etiologic agent of tularemia and has recently been classified as a category

101 clinical course and severity of respiratory tularemia and identifies MMPs as novel targets for thera

102 case-control study of adults with pneumonic tularemia and investigated the environment to identify r

103 cisella tularensis is the causative agent of tularemia and is a category A select agent.

104 cisella tularensis is the causative agent of tularemia and is classified as a category A biodefense a

105 al pathogen that causes the zoonotic disease tularemia and is important to biodefense.

106 s yield new insight into the pathogenesis of tularemia and may have important ramifications in the se

107 ular gram-negative coccobacillus that causes tularemia, and its virulence and infectiousness make it

108 such as Q fever, rickettsioses, brucelloses, tularemia, and other bartonelloses.

109 ority bioterror concerns, including anthrax, tularemia, and plague, are caused by bacteria that acute

110 causing, for example, tuberculosis, malaria, tularemia, and plague.

111 uggest that natural outbreaks of respiratory tularemia are triggered by environmental cues.

112 cisella tularensis biovar A causes pneumonic tularemia associated with high morbidity and mortality r

113 e hundred seventy humans were diagnosed with tularemia between 1981 and 2007, 94% of them during 7 su

114 ting attacks with anthrax, smallpox, plague, tularemia, botulism, or hemorrhagic fever viruses.

115 Diagnosis of tularemia by blood culture and nucleic acid-based diagno

116 cks and tested them in pools for evidence of tularemia by PCR.

117 or infection in a mouse model of respiratory tularemia by signature-tagged mutagenesis.

118 attenuated for virulence in a mouse model of tularemia by the intradermal route.

119 re not notified of the clinical suspicion of tularemia by the service caring for the patient.

120 To characterize cell death in tularemia, C57BL/6 mice were challenged by the intranasa

121 l protein) discriminated between the Spanish tularemia cases and healthy controls.

122 the Schu S4 array with sera from 241 type B tularemia cases in Spain.

123 filed the antibody responses in type A and B tularemia cases in the United States using a proteome mi

124 ould also have utility for diagnosing type B tularemia caused by strains from other geographic locati

125 Inhalational pneumonic tularemia, caused by Francisella tularensis, is lethal i

126 Outbreaks of respiratory tularemia, caused by inhalation of this bacterium, are p

127 ella tularensis (Ft), the causative agent of tularemia, elicits a potent inflammatory response early

128 prerequisite for outbreaks of tularemia in a tularemia-endemic boreal forest area of Sweden and that

129 y which Francisella tularensis, the agent of tularemia, enters host macrophages.

130 glandular (37%) and glandular (25%) forms of tularemia, followed by pneumonic (12%), typhoidal (10%),

131 e development of a vaccine against pneumonic tularemia has been limited by a lack of information rega

132 early hepatic lesions of experimental murine tularemia has not been characterized with specific marke

133 ich is a Gram negative bacterium that causes tularemia, has been classified by the Center for Disease

134 ancisella tularensis, the causative agent of tularemia, has been designated a CDC category A select a

135 tive agent of a fatal human disease known as tularemia, has been used in the bioweapon programs of se

136 ccine currently available to protect against tularemia; however, this unlicensed vaccine is relativel

137 Study of this outbreak of primary pneumonic tularemia implicates lawn mowing and brush cutting as ri

138 A rapidly fatal case of pulmonary tularemia in a 43-year-old man who was transferred to a

139 that these can be used for the diagnosis of tularemia in a deployable format, such as the immunostri

140 te summer is a prerequisite for outbreaks of tularemia in a tularemia-endemic boreal forest area of S

141 hould lead to early suspicion of intentional tularemia in an alert health system; laboratory confirma

142 tion of Bacillus anthracis, botulinum B, and tularemia in complex matrices.

143 predict annual numbers of humans contracting tularemia in Dalarna County, Sweden.

144 tential vaccine candidates against pneumonic tularemia in experimental animals.

145 now report the natural history of pneumonic tularemia in female Fischer 344 rats after nose-only inh

146 rensis is the bacterial pathogen that causes tularemia in humans and a number of animals.

147 Tularemia in humans is caused mainly by two subspecies o

148 Although primary pneumonic tularemia in humans typically occurs by inhalation of ae

149 ancisella tularensis, the etiologic agent of tularemia in humans, is a potential biological threat du

150 ancisella novicida causes a similarly severe tularemia in mice upon inhalation.

151 To define the epidemiology of tularemia in Missouri, and to evaluate practices and out

152 biovar A, possibly reflecting the history of tularemia in North America.

153 udies because it causes a disease similar to tularemia in rodents but is not harmful to humans.

154 A localized outbreak of tularemia in Sweden was investigated.

155 Overall, the pathogenesis of pneumonic tularemia in the female F344 rat model appears to replic

156 mortality or recovery following induction of tularemia in the mouse will improve our understanding of

157 ly previously reported outbreak of pneumonic tularemia in the United States also occurred on the isla

158 veitis may be an infrequent manifestation of tularemia infection, and therefore this infection should

159 rt a case of intraocular inflammation during tularemia infection.

160 ancisella tularensis, the causative agent of tularemia, infects host macrophages, which triggers prod

161 ancisella tularensis, the bacterial cause of tularemia, infects the liver and replicates in hepatocyt

162 ancisella tularensis, the causative agent of tularemia, interacts with host cells of innate immunity

163 Tularemia is a deadly, febrile disease caused by infecti

164 Tularemia is a debilitating febrile illness caused by th

165 Tularemia is a highly infectious zoonotic disease caused

166 Pneumonic tularemia is a life-threatening disease caused by inhala

167 Tularemia is a potentially fatal disease that is caused

168 y vaccine known to confer protection against tularemia is a specific live vaccine strain (designated

169 Tularemia is a zoonosis of humans caused by infection wi

170 The current serological test for tularemia is based on agglutination of whole organisms,

171 Pneumonic tularemia is caused by inhalation of Francisella tularen

172 Tularemia is caused by the category A biodefense agent F

173 Tularemia is caused by the Gram-negative bacterial patho

174 Tularemia is characterized by replication and disseminat

175 Tularemia is considered as a life-threatening potential

176 Clinical recognition of tularemia is essential for prompt initiation of appropri

177 Tularemia is frequently initially misdiagnosed.

178 tential for illicit use, the pathogenesis of tularemia is not well understood.

179 Tularemia is the zoonotic disease caused by the gram-neg

180 y medical and public health professionals if tularemia is used as a biological weapon against a civil

181 ancisella tularensis, the causative agent of tularemia, is a category A bioterrorism agent.

182 ancisella tularensis, the causative agent of tularemia, is a highly virulent microbe.

183 nsis, the highly virulent etiologic agent of tularemia, is a low-dose intracellular pathogen that is

184 ancisella tularensis, the causative agent of tularemia, is a pathogenic bacterium that replicates in

185 Francisella tularensis, the agent of tularemia, is an intracellular pathogen, but little is k

186 cisella tularensis, the etiological agent of tularemia, is capable of infecting a wide range of anima

187 ultative intracellular bacterium that causes tularemia, is considered a biothreat because of its high

188 cisella tularensis, the etiological agent of tularemia, is found throughout the Northern hemisphere.

189 racellular bacterium responsible for causing tularemia, is highly pathogenic and classified as a cate

190 ancisella tularensis, the causative agent of tularemia, is in the top category (category A) of potent

191 ancisella tularensis, the causative agent of tularemia, is most deadly in the pneumonic form; therefo

192 ancisella tularensis, the causative agent of tularemia, is one of the deadliest agents of biological

193 cisella tularensis, the etiological agent of tularemia, is one of the most infectious bacteria known.

194 ancisella tularensis, the causative agent of tularemia, is one of the most infectious bacterial patho

195 ancisella tularensis, the causative agent of tularemia, is phagocytosed by immune cells such as monoc

196 he pathological characteristics of pulmonary tularemia leading to systemic disease, and potentially i

197 arensis novicida, a subspecies that causes a tularemia-like disease in rodents.

198 i, and to evaluate practices and outcomes of tularemia management in general, we conducted a detailed

199 ancisella tularensis, the causative agent of tularemia, modulates the host immune response to gain a

200 ancisella tularensis, the bacterial agent of tularemia, occur infrequently in humans.

201 er of 2000, an outbreak of primary pneumonic tularemia occurred on Martha's Vineyard, Massachusetts.

202 diated protection against lethal respiratory tularemia occurs after mucosal vaccination with inactiva

203 The diagnosis of human cases of tularemia often relies upon the demonstration of an anti

204 been long-standing enzootic transmission of tularemia on the island.

205 s could potentially help in the treatment of tularemia or even be utilized to neutralize the infectio

206 sella tularensis is the etiological agent of tularemia, or rabbit fever.

207 The factors that precipitated the tularemia outbreaks or the proximal determinants of huma

208 associate responsiveness to polyamines with tularemia pathogenesis and define FTL_0883/FTT_0615c as

209 in vitro-derived findings may be relevant to tularemia pathogenesis in the mammalian host.

210 hages and neutrophils play distinct roles in tularemia pathogenesis, such that macrophages are major

211 ct bacterial dissemination after respiratory tularemia, provide new insights regarding the pathologic

212 ical investigations and characterizations of tularemia source outbreaks.

213 ancisella tularensis, the causative agent of tularemia, survives and proliferates within macrophages

214 ntly preceded the median onset time of human tularemia (temporal correlation, 0.76; P < .05).

215 attenuation of virulence in a mouse model of tularemia that could be complemented by addition of tolC

216 In a mouse model of tularemia, the DeltafupA mutant was attenuated, but the

217 livered intranasally can prevent respiratory tularemia through a mechanism that is at least partially

218 a with transmission of the bacterial disease tularemia to humans, and model the annual variation of d

219 were obtained in a mouse model of pneumonic tularemia using the highly virulent F. tularensis subspe

220 ta suggest that improved efficacy of current tularemia vaccine platforms will require targeting appro

221 The frequency for tularemia was 6.91%.

222 ther infectious and non-infectious etiology, tularemia was diagnosed by advanced serology consisting

223 fort to develop a rapid diagnostic assay for tularemia, we investigated the use of TaqMan 5' hydrolys

224 In the murine model of pulmonary type A tularemia, we showed the presence of intraerythrocytic b

225 The splenic Gr-1(+) CD11b(+) cells in tularemia were a heterogeneous population that could be

226 had symptoms suggestive of primary pneumonic tularemia, were ill between May 15 and October 31, 2000,

227 erring protection against lethal respiratory tularemia when given 24-48 h postexposure.

228 associated with protection from respiratory tularemia, whereas a deregulated host response leading t

229 causes lethal infection that resembles human tularemia, whereas the LD50 for an intradermal infection

230 igate cell-mediated immune responses against tularemia, whose sporadic incidence makes clinical trial

231 izes what is known about the pathogenesis of tularemia with a focus on bacterial surface components s

232 A weapon using airborne tularemia would likely result 3 to 5 days later in an ou

233 ause this strain was attenuated in pneumonic tularemia yet induced a protective immune response.